KBI acquires biologics operations in Colorado

14-May-2014 - USA

KBI Biopharma has signed an agreement with Merck & Co., Inc. to acquire Merck’s microbial process development and manufacturing operations in Boulder, Colorado, effective May 1, 2014. Under the agreement, KBI will provide ongoing development and manufacturing services to Merck, as well as to third party customers.

“We are very pleased to continue to advance our partnership with Merck, and to welcome this very highly regarded team of scientists in Boulder to the KBI team,” stated Joe McMahon, KBI’s President and CEO.  “KBI will now offer expanded microbial development and manufacturing services up to 1500L scale, as well as continuing to offer our current full range of process development, analytical and formulation development and mammalian manufacturing services up to 2000L.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances